– Total revenues of $881 million in the first quarter
– Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.
– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines
– Plenary Scientific Session will feature.
– Total revenues of $919 million in the third quarter
– Jakafi® net product revenues of $636 million in Q3 23, $1.9 billion YTD 2023, driven by growth in total patients across all.
Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held. | May 25, 2023